A Checklist for Reporting the Results of Clinical Research Studies in Cancer 1
Papers reviewing the adequacy of reporting research results in the medical literature have been published regularly for several decades, with the distressingly common finding that reporting of basic elements of design, conduct, or analysis is often inadequate (1 -3) . Some of the problems discovered are major ones, calling into question important conclusions of the paper. In recent years, efforts of editors of clinical journals have improved the situation. For example, the Consolidated Standards of Reporting Trials (CONSORT) guidelines (4), aimed at improving the reporting of randomized clinical trials, have been adopted by over 150 journals. However, reports of randomized trials represent only a small fraction of the clinical research literature, including those published in Clinical Cancer Research. Early phase nonrandomized clinical trials and studies of prognostic (5), predictive (6), surrogate (7) or other biomarkers (8, 9) in cancer prevention, diagnosis (10), prognosis, and therapy are much more common.
The following checklist gives some guidance to contributors and reviewers of manuscripts submitted to Clinical Cancer Research by providing a brief summary of items that should be addressed in the reporting of clinical research studies. Some clinical trial -specific items are included for completeness (11 -16) , but for the special case of a randomized clinical trial, the CONSORT guidelines should be followed (http://www. consort-statement.org/revisedstatement.htm). 
Checklist

